DisperSol Technologies was founded in 2007 and evolved from a research collaboration with the College of Pharmacy at The University of Texas at Austin. The focus of this collaboration was to adapt and apply a unique plastics processing technology to pharmaceutical manufacturing. KinetiSol® emerged from this research as an innovative technology for the production of drug-polymer composite systems, especially amorphous solid dispersions.
Watch our video to see how it works
KinetiSol’s drug-polymer systems can be made with drugs and excipients that cannot be used in any other commercial manufacturing technologies. The advantage of KinetiSol is that our formulations can improve the solubility and bioavailability of poorly water-soluble drugs. They can also impart tremendous physical toughness to tablets and multiparticulates, making drugs much harder to abuse and preventing dose dumping in alcohol or other solvents.
OUR BUSINESS MODEL
DisperSol is commercializing the KinetiSol platform through a combination of external partnerships and internal drug development programs. DisperSol collaborates with major pharmaceutical companies, chemical companies, and research institutions on applications of the KinetiSol technology to the most challenging drug molecules.
DisperSol is capable in its Texas facility to support product development activities from preclinical development through to commercial GMP manufacturing.